Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively,representing 68% and 74% year-over-year growth SUNOSI® 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively,representing 40% and 32% year-over-year growth SYMBRAVO® 4Q and full year 2025 net product sales of $4.1 million and $ ...

(All amounts in US$ unless otherwise stated) TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) today announced that its Board of Directors has approved a $73 million construction budget and established an execution schedule to achieve mechanical completion of its cobalt sulfate Refinery north of Toronto, marking a significant step toward bringing North America’s first battery-grade cobalt refinery into operation. Commiss ...

Core Insights - Foghorn Therapeutics Inc. has appointed Ryan Maynard as Chief Financial Officer effective February 23, 2026, bringing over 25 years of executive experience in the biopharmaceutical sector [1][2][3] Company Overview - Foghorn Therapeutics is focused on developing a new class of medicines that target genetically determined dependencies within the chromatin regulatory system, utilizing its proprietary Gene Traffic Control® platform [4] Leadership and Experience - Ryan Maynard has a strong background in financial strategy and operational performance, having previously served as CFO at Cara Therapeutics, where he led financial strategy and strategic transactions [2][3] - He has raised over $1 billion through public and private financings and played a significant role in the FDA approval and commercial launch planning of TAVALISSE [3] - Maynard has also executed a reverse merger and raised $37.5 million through a non-dilutive royalty deal at Cara Therapeutics [3] Strategic Goals - The company aims to advance its first-in-class pipeline and is currently in dose escalation for its lead program in partnership with Lilly, while also preparing its selective degrader portfolio for clinical trials [2][3]

Core Insights - C4 Therapeutics has initiated the Phase 2 MOMENTUM trial for cemsidomide in combination with dexamethasone, targeting relapsed/refractory multiple myeloma patients, with enrollment expected to complete by Q1 2027 [1][7] - The Phase 1b trial of cemsidomide in combination with elranatamab is set to begin in Q2 2026, supporting a regulatory strategy for accelerated approvals in multiple myeloma [2][3] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation science, aiming to develop innovative therapies for difficult-to-treat diseases [10] - The company's lead candidate, cemsidomide, is an investigational oral IKZF1/3 degrader, showing promising safety and efficacy profiles in prior trials [4][10] Trial Details - The Phase 2 MOMENTUM trial is an open-label, single-arm study enrolling approximately 100 patients, evaluating cemsidomide at a dose of 100 µg, administered in a 14 days on and 14 days off schedule [2][5] - The primary endpoint of the trial is the overall response rate as per International Myeloma Working Group criteria, assessed by an independent review committee [5][9] Upcoming Milestones - Further analysis of the completed Phase 1 trial of cemsidomide in combination with dexamethasone is anticipated in mid-2026 [7] - The Phase 1b trial of cemsidomide with elranatamab will explore safety and preliminary efficacy, contributing to the broader development strategy for cemsidomide [6][3] Industry Context - Multiple myeloma is a rare blood cancer with approximately 36,000 new diagnoses annually in the U.S., highlighting the need for new therapeutic options as most patients eventually relapse [9] - IKZF1/3 degraders are foundational therapies in multiple myeloma treatment, and cemsidomide aims to enhance treatment efficacy and patient outcomes [9]

Core Insights - Loblaw Companies Limited plans to invest $2.4 billion in 2026 as part of a 5-year strategy to invest a total of $10 billion in Canadian communities by 2030 [1][3] - The investment aims to expand and renovate the store network, enhance supply chain capabilities, and create approximately 9,700 jobs across Canada [2][4] Investment Details - In 2026, Loblaw will open 70 new stores, including 34 Shoppers Drug Mart / Pharmaprix pharmacies and care clinics, and 31 No Frills and Maxi stores [2] - The company will also renovate 191 existing stores and continue construction of a 1.2 million square foot automated distribution center in Caledon, Ontario [2] Economic Impact - This investment reinforces Loblaw's role as a significant contributor to the Canadian economy and aims to provide better access to value for customers [3][4] - The job creation will be distributed across various regions: Eastern Canada (4 new stores, 600 jobs), Quebec (15 new stores, 1,985 jobs), Ontario (27 new stores, 3,775 jobs), and Western Canada (24 new stores, 3,400 jobs) [7]

Core Insights - TDG Gold Corp. has discovered a new lens of volcanogenic massive sulphide (VMS) mineralization, named the 4300 Zone, located below the past-producing Hidden Creek Mine at the Anyox Project in British Columbia [1][4][6]. Exploration and Discovery - The Hidden Creek Mine, operational from 1914 to 1935, produced 22 million tons of copper at a grade of 1.57% Cu before ceasing operations due to low metal prices during the Great Depression [2]. - Recent drilling by TDG has outlined the 4300 Zone, with drill hole ANY-25-002 intersecting a broad interval of massive sulphides grading 2.1% CuEQ over 25.08 meters, including higher-grade sub-intervals averaging 2.5% CuEQ over 14.80 meters [5][6]. - The 4300 Zone remains open for expansion in all directions, with additional drilling planned for 2026 [3][6]. Geological Context - The mineralization processes at Hidden Creek are typical of Besshi VMS systems, characterized by copper-rich deposits with subordinate concentrations of zinc, gold, silver, and cobalt [9][10]. - The geological environment consists of submarine volcanic rocks that host the VMS mineralization, with the 4300 Zone located at a depth of 900 meters below the surface [10][11]. Future Plans - TDG is well-funded and plans to continue exploration activities at Anyox, which has year-round tidewater access [4][6]. - Geophysical surveys have identified multiple new targets, and drilling of the 4300 Zone will resume in March 2026 after further data refinement [12][6].

Core Viewpoint - Plug Power Inc. is set to announce its 2025 fourth quarter and year-end results on March 2, 2026, highlighting its ongoing leadership in the hydrogen economy [1]. Group 1: Company Overview - Plug Power is a global leader in comprehensive hydrogen solutions, focusing on building a fully integrated ecosystem that includes production, storage, delivery, and power generation [3]. - The company is a first mover in the hydrogen industry, providing essential components such as electrolyzers, liquid hydrogen, fuel cell systems, storage tanks, and fueling infrastructure [3]. Group 2: Industry Position and Achievements - Plug Power has deployed over 72,000 fuel cell systems and 285 fueling stations, making it the largest user of liquid hydrogen [4]. - The company operates hydrogen plants in Georgia, Tennessee, and Louisiana, with a production capacity of 40 tons per day, ensuring a reliable and domestically produced hydrogen supply [4]. - Plug Power serves major global clients, including Walmart, Amazon, Home Depot, BMW, and BP, showcasing its significant role in advancing energy independence and decarbonization [5].

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the event. About Apelli ...

Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed re ...

TORONTO and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- illumin Holdings Inc. (TSX:ILLM, OTCQB:ILLMF) (“illumin” or “Company”), a leader in digital advertising technology that empowers marketers to make smarter decisions about communicating with online consumers, announces that it will report its fourth quarter and year-end 2025 financial results before market open on Friday, March 13, 2026. Investors and analysts are invited to join a live webcast on Friday, March 13, 2026, at 8:30 AM ET, where CEO Simon C ...